Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Evidence at Molecular Level Supports Link Between Environmental Estrogens and Breast Cancer

September 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 9
Volume 11
Issue 9

Data from two studies presented at the 88th Annual Meeting of the American Association for Cancer Research (AACR)

Data from two studies presented at the 88th Annual Meeting of the AmericanAssociation for Cancer Research (AACR) have added evidence to support anassociation between environmental estrogens and breast cancer. Lifetimeexposure to endogenous estrogens is known to be a risk factor for breastcancer. However, there is uncertainty about whether environmental estrogenssuch as DDT are definitively linked to breast cancer. Two large epidemiologicalstudies conducted in the 1990s produced conflicting findings regardingthe correlation between increasing concentrations of DDT metabolites andincidence of breast cancer. Moreover, little is known about the potentialmechanisms by which endogenous or environmental estrogens convert normalbreast epithelial cells into abnormal cells.

Scientists from the Karmanos Cancer Institute in Detroit examined theeffects of estradiol and five closely related organochlorine pesticideson cell growth in two estrogen receptor-positive human breast epithelialcell lines: precancerous cells and human breast cancer cells. Organochlorinepesticides have been associated with the development of breast cancer becauseof their estrogenic properties. Those selected for this study act as estrogenswith actions mediated through the estrogen receptor.

Pesticide Combinations More Lethal

Using a special assay, the investigators found that when the pesticideswere administered individually, they caused the human breast epithelialcells to proliferate, but only when they were administered at 100- to 1,000-foldhigher levels than estradiol. However, when the pesticides were administeredin combination, they caused cell proliferation similar to that observedwith physiological concentrations of estradiol.

According to study investigator, Malathy Shekhar, PhD, "To date,there is no conclusive proof that endogenous estrogens cause breast cancer.The only evidence comes from epidemiological studies showing an associationbetween an individual's total cumulative exposure to estrogen and breastcancer. In order to provide stronger evidence for this association, westudied the possible mechanisms by which estrogens cause malignancy. Weused an estrogen receptor-positive precancerous cell line that we developed."

Dr. Shekhar added, "We found that estradiol and the pesticidesactivated estrogen-mediated responses via estrogen receptors on this cellline, suggesting that some environmental estrogens, particularly in combination,may be involved in breast cancer progression. This is an important findingbecause environmental estrogens such as DDT still pose a threat to humanseven though their use has been banned for many years. Not only does DDTremain in the environment for many years, but it also concentrates in adiposetissue in the breast and other organs in the body."

In a second study reported at the AACR Annual Meeting, researchers atthe University of Rochester School of Medicine and Dentistry investigatedwhether DDT isomers, different chemical forms of DDT, and their metabolitescan bind to and activate estrogen receptors in humans and act as estrogens.Results from previous studies had indicated that certain DDT compoundsspecifically bind to and activate rodent and avian estrogen receptors,but no data have been available on how these compounds interact with thehuman estrogen receptor at the molecular level.

Rat vs Human Receptors

Experiments conducted by researchers at the University of RochesterSchool of Medicine and Dentistry measured the ability of DDT isomers andmetabolites to bind to and activate the human estrogen receptor. The studiesfound that many of the DDT compounds had more than 100-fold higher affinitiesfor the human estrogen receptor than for the rat estrogen receptor. Usinga cellular model that expresses human estrogen receptors and provides ameasurable signal when this receptor is activated, the researchers screenedthe DDT compounds for estrogenic activity. They found that the DDT isomersand metabolites that bound to the human estrogen receptor were able toactivate it in a concentration-dependent manner and elicit an additiveresponse when administered with another DDT metabolite or with estradiol.

According to study investigator, Clarice W. Chen, MS, "Of particularsignificance is the finding that both DDT isomers bind to the human estrogenreceptor, whereas only one binds with measurable affinity to the rat estrogenreceptor. Moreover, many DDT metabolites have a substantially higher affinityfor the human than the rat estrogen receptor, even though the main metaboliteof DDT does not. Our data suggest the metabolites that activate the humanestrogen receptor do so with the same potency as the parent compounds,and this activation is additive to that of another DDT compound or estradiol.These findings differ from those using other animal models and suggestthat humans may be more susceptible to DDT metabolites than other species."

Articles in this issue

UFT: East Meets West in Drug Development
UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support
Rationale for Phase I Study of UFT Plus Leucovorin and Oral JM-216
Postoperative Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer
5-FU or UFT Combined With Leucovorin for Previously Untreated Metastatic Colorectal Cancer
UFT in Gastric Cancer: Current Status and Future Developments

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 12th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 12th 2025
Podcast

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 12th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 12th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 12th 2025
Article

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
September 12th 2025
Article
Related Content

ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 12th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 12th 2025
Podcast

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 12th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 12th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 12th 2025
Article

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
September 12th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.